Dina Ron

Dina Ron

Education/ Resume

1976 – BSc (cum laude), Biology Department, Ben-Gurion University of the Negev
1979– MSc (cum laude), Biology Department, Ben-Gurion University of the Negev
1984– PhD, Biology Department, Ben-Gurion University of the Negev
1984- 1987, Post-Doctoral fellow, National Cancer Institute, NIH, USA
1987 –1990, Visiting Associate, National Cancer Institute, NIH, USA
1990– Visiting Scientist, National Cancer Institute, NIH, USA

Research Summary

We study mechanisms that inhibit tumor initiation and progression, the link between inflammation and cancer, and exploiting the knowledge gained for cancer therapy.


2015- 2016 Excellency grant from the Israel Cancer Association
1994 –1998 Grant for Research Center of Excellence, Israel Science Foundation.

Selected Publications

Preger, E., Ziv, I., Shabtay, A., Sher, I., Tsand, M, Dawid, B.I., Altuvia, Y. and Ron, D. (2004) Alternative splicing generates a novel isoform of  the human sef gene with altered subcellular localization and specificity. Proc. Natl. Acad. Sci. U.S.A. 101, 1229-1234.

  • Sher, I., Zisman-Rozen, S., Eliahu, L., Whitelock, J.M., Maas-Szabowski, N., Yamada, Y., Breitkreutz, D.,. Fusenig, N.E., Arikawa-Hirasawa, E., Iozzo, R.V., Bergman, R. and Ron, D. (2006) Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermis formation. J Biol. Chem. 28, 5178-87. (Cited in the Faculty of 1000).
  • Zisman-Rozen, S., Fink, D., Ben-Izhak, O., Fuchs, Y., Brodski, A., Kraus, M.H., Bejar J. and Ron, D. (2007) Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a vareity of human carcinomas. Oncogene 26, 6093-6098
  • Fuchs Y., Brunwasser M., Haif S., Haddad J., Shneyer B., Goldshmidt-Tran O., Korsensky L., Abed M., Zisman-Rozen S., Koren L., Carmi Y., Apte R., Yang RB., Orian A., Bejar J. and Ron D. (2012) Sef Is an Inhibitor of Proinflammatory Cytokine Signaling, Acting by Cytoplasmic Sequestration of NF-κB. Developmental Cell 23, 611-23.  
  • Mishel S., Shneyer B., Korsensky l., Goldshmidt-Tran O.,  Haber T., Machluf M., and Ron D. (2017) Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth. Sci. Reports, 7(1):15060
  • Korsensky L, Haif S, Heller R, Rabinovitz S, Haddad-Halloun J, Dahan N., and Ron D. (2019) The tumor suppressor Sef is a scaffold for the classical NF-κB/RELA:P50 signaling module. Cell Signal. 59:110-121
read more
Open Positions

We are seeking for highly motivated post-doctoral fellows for studying mechanisms that suppress tumor growth and for developing new approaches for cancer therapy

Also available to you on social media